developing the world’s first

percutaneous catheter placed pulsating aortic stent graft

for low hemolysis long term or short term circulatory assist support.

PulseGraft working in partnership with VibroCell

is developing pulsating arteriovenous (AV) grafts and fistulas coupled with harmonic resonance vibrational energy technology from VibroCell for providing blood clot free reliable dialysis access. The product development also includes bioelectric signaling to reduce the risk of infections and to accelerate healing after placement.

Dialysis

is a lifesaving treatment when you have kidney failure. To keep up a regular dialysis schedule, patients need a sturdy dialysis access where blood can flow in and out of the body. They must have a good, steady blood flow. These access grafts often fail due to blood clot formation and/or infection. PulseGraft and VibroCell have teamed up to solve this highly dangerous problem.

Any type of current technology dialysis access has high risk of failure. So it’s highly important to patients to protect their access by preventing blood clotting or infection

PulseGraft’s two arteriovenous product developments:

  • PulseGraft AV – Is a pulsating arteriovenous (AV) graft supported by VibroCell harmonic resonance vibrational energy, and bioelectric signaling for preventing infections, made for insertion between an artery and a vein, usually in the upper arm or forearm. This pulsating graft is meant to be a good choice if you have small veins or other problems.

 

  • PulseGraft AV Fistula – Is a pulsating arteriovenous (AV) fistula supported by VibroCell harmonic resonance vibrational energy, and bioelectric signaling for preventing infections and accelerating healing, made to be directly connected from an artery to a vein, usually in the upper arm or forearm. This PulseGraft AV Fistula is meant to last longer than a standard graft, and is expected to be less likely to have blood clots or get infected. The PulseGraft AVE fistula, is designed to reduce the normal several months needed to heal after placement down to a few weeks. The PulseGraft AV Fistula has the goal to be the most dependable access device for dialysis patients with the least chance of blood clotting and infection.